Business
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD).Regulatory submission is planned in the first half of 2026. TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOB
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"Kyowa Kirin","displaySize":"","headline":null,"caption":"Kyowa Kirin","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/K77r3CFldRtJVVNCB0.bKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867","width":300,"height":58}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD).","length":262,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory submission is planned in the first half of 2026.","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":453,"olType":false},{"type":"text","content":"TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization. This business decision is the result of a strategic portfolio prioritization by Amgen. The companies are initiating a smooth and orderly transition of the program, with a focus on ensuring continuity for participants currently enrolled in clinical trial programs. Amgen, who has partnered with Kyowa Kirin on numerous investigational therapies over 41 years, will continue to manufacture rocatinlimab.","length":811,"tagName":"p"},{"type":"text","content":"“Kyowa Kirin is confident in the potential of rocatinlimab to address critical unmet needs for patients with moderate-to-severe atopic dermatitis who are looking for new, long-lasting options that may address the chronic nature of unpredictable flares,...